| 1.54 -0.05 (-3.14%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.05 | 1-year : | 2.33 |
| Resists | First : | 1.75 | Second : | 2 |
| Pivot price | 1.62  |
|||
| Supports | First : | 1.36 | Second : | 1.13 |
| MAs | MA(5) : | 1.52  |
MA(20) : | 1.65 |
| MA(100) : | 1.74 |
MA(250) : | 2.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 25.6 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 4.55 | Low : | 1.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRDF ] has closed above bottom band by 37.8%. Bollinger Bands are 10.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.63 - 1.64 | 1.64 - 1.65 |
| Low: | 1.52 - 1.53 | 1.53 - 1.54 |
| Close: | 1.53 - 1.54 | 1.54 - 1.55 |
Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias. Additionally, Cardiff Oncology is advancing TROV-054 in Phase 1b/2 trials, exploring its combination with FOLFIRI and bevacizumab, and TROV-053 in a Phase II clinical trial, where it is being assessed alongside Zytiga for metastatic castration-resistant prostate cancer. Established in 1999, the company, which primarily supplies its pharmaceutical innovations to manufacturers, was originally known as Trovagene, Inc. It officially rebranded to Cardiff Oncology, Inc. in May 2012.
Thu, 11 Jun 2026
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Wed, 03 Jun 2026
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus
Wed, 03 Jun 2026
Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3 - Stock Titan
Mon, 01 Jun 2026
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 6.671e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 18,320 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.707e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -31 % |
| Return on Assets (ttm) | 341.4 % |
| Return on Equity (ttm) | -44.3 % |
| Qtrly Rev. Growth | 525000 % |
| Gross Profit (p.s.) | -45.89 |
| Sales Per Share | -62.35 |
| EBITDA (p.s.) | -2.28603e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 4.1 |
| Dividend | 0 |
| Forward Dividend | 1.802e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|